FiercePharma11d
Sanofi's consumer health arm Opella secures FDA green light to pursue OTC Cialis study
After hitting a regulatory roadblock in 2022, Sanofi’s consumer healthcare business Opella has secured the FDA’s blessing to ...
Sanofi says FDA lifted clinical hold on trial for Cialis OTC switch
Sanofi’s (NASDAQ:SNY) consumer healthcare unit Opella announced Tuesday that the U.S. FDA has lifted a clinical hold on a ...
pharmaphorum5y
Sanofi licenses OTC Tamiflu rights for the US market
Tamiflu was a blockbuster product for Roche over a ... Tamiflu has been approved in New Zealand as an OTC drug since 2007, and that will likely assist Sanofi as it tries to persuade the FDA ...
Positive Report for Sanofi (SNYNF) from DZ BANK AG
Sanofi (SNYNF – Research Report) received a Buy rating and price target from DZ BANK AG analyst Elmar Kraus today. The company’s shares ...
Kepler Capital Sticks to Its Hold Rating for Sanofi (SNYNF)
In a report released on January 30, David Evans from Kepler Capital maintained a Hold rating on Sanofi (SNYNF – Research Report), with a price ...
Nasdaq11d
Sanofi's Opella: FDA Lifts Clinical Hold On OTC Cialis Trial
(RTTNews) - Sanofi's Consumer Healthcare division ... from a prescription-only medication to an over-the-counter option. With this decision, the actual use trial can now proceed, marking Cialis ...
pharmaphorum1y
Sanofi says new drugs can add €10bn to sales by 2030
The three pipelines-in-a-product are anti-OX40 ... through 2030 and beyond.” Sanofi's consumer healthcare unit Opella could finally be able to bring an OTC PDE-5 inhibitor for erectile ...
Sanofi plans share buybacks, signals more deals post Opella sale
Sanofi said on Thursday it would buy back 5 billion euros ($5.21 billion) in shares this year and could be more active with acquisitions in the near term as the drugmaker moves towards selling a large ...